Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model

Annals of Surgery

Volumn 231, Issue 5, 2000, Pages 762-771

  Jarnagin, William R ^a,b   Delman, Keith ^a   Kooby, David ^a   Mastorides, Stephen ^b   Zager, Jonathan ^a   Brennan, Murray F ^a   Blumgart, Leslie H ^a   Federoff, Howard ^c   Fong, Yuman ^a  

^a Department of Surgery ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; INTERLEUKIN 12;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CANCER RECURRENCE; CONTROLLED STUDY; GENE THERAPY; HERPES SIMPLEX VIRUS; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BETA-GALACTOSIDASE; GENE THERAPY; GENETIC VECTORS; HEPATECTOMY; INTERLEUKIN-12; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NEOPLASM RECURRENCE, LOCAL; RATS; RATS, INBRED BUF; SIMPLEXVIRUS;

EID: 0034061526     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200005000-00017     Document Type: Article

References (65)

1. Fan S, Lai ECS, Lo C, Ng IOL, Wong J. Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg 1995; 130:198-203.
2. Fong Y, Fortner J, Sun R, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309-321.
3. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19:59-71.
4. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77:1254-1262.
5. Fong Y, Blumgart LH, Cohen AM. Surgical treatment of colorectal metastases to the liver. CA 1995; 45:50-62.
6. Fisher ER, Fisher B. Experimental studies of factors influencing hepatic metastases. Cancer 1959; 12:929-932.
7. Karpoff HM, Tung C, Ng B, Fong Y. Interferon gamma protects against hepatic tumor growth in rats by increasing Kupffer cell tumoricidal activity. Hepatology 1996; 24:374-379.
8. Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998; 228:756-762.
9. Kemeny N, Huang Y, Cohen AM, et al. Randomized study of hepatic arterial infusion and systemic chemotherapy versus systemic chemotherapy alone as adjuvant treatment following resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039-2048.
10. Karpoff HM, D'Angelica M, Blair S, Brownlee MD. Federoff H. Fong Y. Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon. J Clin Invest 1997; 99:799-804.
11. Fidler IJ. Systemic macrophage activation with liposome-entrapped immunomodulators for therapy of cancer metastasis. Res Immunol 1996; 143:199-204.
12. Kawata A, Une Y, Hosokawa M, et al. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus Adriamycin alone. Am J Clin Oncol 1995; 18:257-262.
13. Cavallo F, Giovarelli M, Gulino A, et al. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to non-immunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 1991; 149:3627-3635.
14. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors in mice treated with interleukin-2 gene-modified tumor cells. J Exp Med 1993; 177:1127-1134.
15. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 1994; 54:6022-6026.
16. Saito S, Bannerji R, Gansbacher B, et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 1994; 54:3516-3520.
17. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172:1217-1224.
18. Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991; 173:889-897.
19. Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-lambda genes. J Immunother 1993; 14:191-201.
20. Vieweg J, Rosenthal FM, Bannerji R, et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994; 54:1760-1765.
21. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254:713-716.
22. Porgador A, Tzehoval E, Katz A, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992; 52:3679-3686.
23. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90:3539-3543.
24. D'Angelica M, Tumg C, Allen P, et al. Herpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity. Mol Med 1999; 5:606-616.
25. Karpoff HM, Kooby D, D'Angelica M, et al. Efficient cotransduction of tumors by multiple herpes simplex vectors: implications for tumor vaccine production. Cancer Gene Ther (in press).
26. Tahara H, Zeh HJ III, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54:182-189.
27. Bruna MJ, Lusitro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993; 178:1223-1230.
28. Vagliani M, Rodolfo M, Cavallo F, et al. Interleukin 12 potentiates the curative effect of a vaccine based on. Cancer Res 1996; 56:467-470.
29. Rao JB, Chamberlain RS, Bronte V, et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol 1996; 156: 3357-3365.
30. Kramm CM, Chase M, Herrlinger U, et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997; 8:2057-2068.
31. Federoff HJ. Growth of replication defective herpes virus amplicon vectors and their use for gene transfer. In: Spector DL, Leinwand L, Goldman R, eds. Cell Biology: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Press; 1996.
32. Geller AI, Keyomarsi K, Bryan J, Pardee AB. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci USA 1990; 87:8950-8954.
33. Geller AI, Breakefield XO. A defective HSV-1 vector expresses Escherichia coli B-galactosidase in cultured peripheral neurons. Science 1988; 241:1667-1669.
34. Fong Y, Federoff HJ, Brownlee M, Blumberg D, Blumgart LH, Brennan MF. Rapid and efficient gene transfer in human hepatocytes by herpes viral vectors. Hepatology 1995; 22:723-729.
35. Ley V, Langlade-Demoyen P, Kourilsky P, Larrson-Sciard E. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur J Immunol 1991; 21:851-854.
36. Rubin JT. Interleukin-2: its biology and clinical application in patients with cancer. Cancer Invest 1993; 11:460-472.
37. Rosenberg SA. Adoptive immunotherapy for cancer. Sci Am 1990; 262:34-39.
38. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J NCI 1993; 85:622-632.
39. Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154:6466-6474.
40. Ahuja SS, Mummidi S, Malech HL, Ahuha SK. Human dendritic cell (DC)-based anti-infective therapy: engineering DCs to secrete functional IFN-y and IL-12. J Immunol 1998; 161:868-876.
41. Myers JN, Mank Seymour A, Zitvogel L, et al. Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope 1998; 108:261-268.
42. Matsumoto G, Sunamura M, Shimamura H, et al. Adjuvant immunotherapy using fibroblasts genetically engineered to secrete interleukin 12 prevents recurrence after surgical resection of established tumors in a murine adenocarcinoma model. Surgery 1999; 125:257-264.
43. Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol 1984; 2:336-53.
44. Reinhart JJ, Malspeis L, Young D, Neidhart JA. Phase I-II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma. Cancer Res 1986; 46:5364-5367.
45. Vadhan-Raj S, Al-Katib A, Bhalla R, et al. Phase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol 1986;4:137.
46. Abbruzzese JL, Levin B, Ajani JA, et al. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res 1989; 49:4057-4061.
47. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57:503-512.
48. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992; 257:548-551.
49. Chen L, Chen D, Block E, O'Donnel M, Kufe DW, Clinton SK. Eradication of murine bladder carcinoma by intratumor injection of bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 1997; 159:351-359.
50. Lattime EC, Lee SS, Eisenlohr LC, Mastrangelo MJ. In situ cytokine gene transfection using vaccinia virus vectors. Semin Oncol 1996; 23:88-100.
51. Hogan SP, Foster PS, Tan X, Ramsay AJ. Mucosal IL-12 gene delivery inhibits allergic airway disease and restores local antiviral immunity. Eur J Immunol 1998; 28:413-423.
52. Robinson BW, Mukherjee SA, Davidson A, et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 1998; 21:211-217.
53. D'Angelica M, Karpoff H, Halterman M, et al. In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors. Cancer Immunol Immunother 1999; 47:265-271.
54. Breakefield XO. Gene delivery into the brain using virus vectors. Nature Gen 1993; 3:187-189.
55. Tung C, Federoff HJ, Brownlee M, et al. Rapid production of IL-2 secreting tumor cells by HSV-mediated gene transfer: implications for autologous vaccine production. Hum Gene Ther 1996; 7:2217-2224.
56. Brunda MJ. Interleukin-12. J Leukocyte Biol 1994; 55:280-288.
57. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 1992; 143:127-142.
58. Williams NJ, Harvey JJ, Booth RF, Knight SC. Interleukin-12 restores dendritic cell function and cell-mediated immunity in retrovirus-infected mice. Cell Immunol 1998; 183:121-131.
59. O'Hara RJ, Greenman J, MacDonald AW, et al. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res 1998; 4:1943-1948.
60. O'Hara RJ, Greenman J, Drew PJ, et al. Impaired interleukin-12 production is associated with a defective anti-tumor response in colorectal cancer. Dis Colon Rectum 1998; 41:460-463.
61. Rakhmilevich AL, Janssen K, Turner J, CuIp J, Yang NS. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther 1997; 8:1303-1311.
62. Scott P. IL-12: initiation cytokine for cell-mediated immunity. Science 1993; 260:496-497.
63. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, OGarra A, Murphy KM. Development of TA1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260:547-549.
64. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM. Human Mig chemokine: biochemical and functional characterization. J Exp Med 1995; 182:1301-1314.
65. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993; 259:368-370.